Serif Biomedicines
Last verified 2026-05-13. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $50.0Mattributed |
|---|---|
| Latest round | seed, $50.0M, 2026-04-24attributed |
| Founded | 2024 |
| Headquarters | Cambridge |
| Industry | bio |
| Stage | seed |
| Website | serifbio.com |
Serif Biomedicines is a biotech developing therapeutics targeting underserved disease areas. It serves patients with severe diseases that lack effective therapies and the pharma partners that license its assets. The platform combines biology and computational discovery to identify novel drug targets.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2026-04-24 | seed | $50.0M | undisclosed |
Provenance
| Fact | Status | Basis |
|---|---|---|
| Seed, $50.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $50.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | serifbio.com, read 2026-05-13 |
| Description | self-reported | serifbio.com, read 2026-05-13 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.